Phaseline

Companies › LeonaBio

LeonaBio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lasofoxifene
Estrogen receptor modulator
ESR2, ESR1Phase 3Metastatic Breast CancerApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05696626LasofoxifenePhase 3Metastatic Breast CancerOncologyApr 2027

From the company's SEC filings

Cash and short-term investments of $51m on 2026-06-30; operating cash outflow about $77m a year; runway about 8 months at that burn, to Feb 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ESR2 (1) ESR1 (1)

Companies with the same targets

Pfizer Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Azure Biotech AstraZeneca Roche Eurofarma Laboratorios Eli Lilly Shanghai Best-Link Bioscience Stemline Therapeutics Atossa Therapeutics

Companies built like this

Atossa Therapeutics Shanghai Best-Link Bioscience Can-Fite BioPharma RenovoRx Intensity Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.